Asthma across the ages: Knowledge gaps in childhood asthma

Abstract

The Eunice Kennedy Shriver National Institute of Child Health and Human Development convened an Asthma Group in response to the Best Pharmaceuticals for Children Act (BPCA). The overall goal of the BPCA Program is to improve pediatric therapeutics through preclinical and clinical drug trials that lead to drug labeling changes. While significant advances have been made in the understanding and management of asthma in adults with appropriately labeled medications, less information is available on the management of asthma in children. Indeed, many medications are inadequately labeled in children. In general, the younger the child, the less information there is available to guide clinicians. Since asthma often begins in early childhood, it is incumbent upon us to continue to address the primary questions raised in this review and carefully evaluate medications used to manage asthma in children. Meanwhile, continued efforts should be made in defining effective strategies that reduce the risk of exacerbations. If the areas of defined need are addressed in the coming years, namely prevention of exacerbations and progression of disease, as well as primary intervention, we will see continuing reduction in asthma mortality and morbidity along with improved quality of life for children with asthma.

Future Research Directions in Asthma. An NHLBI Working Group Report

“…As indicated by the asthma phenotypes and endotypes working group, there is substantial heterogeneity in "asthma," and this heterogeneity is reflected by a broad range of therapeutic responses in clinical trials (8,(25)(26)(27) …”

Examining causes of the urban (inner city) asthma epidemic: Implementing new management strategies

“…However, we still need medications that prevent disease progression and the onset of the dis- Table 1 Key factors in asthma management for inner city children Asthma deaths and hospitalizations are decreasing but the African American/black population still bears a heavier burden of the disease It is important to standardize and harmonize asthma care; there is also a need for collaboration to address health disparities in asthma care Asthma care must be focused on achieving asthma control by preventing asthma exacerbations, progression, and adverse effects to medications Response to new medications has been linked to specific biomarkers, e.g., sputum or blood eosinophil count with anti-interleukin-5 therapy It is possible that poorly controlled asthma may lead to chronic obstructive lung disease, such as the "asthmachronic obstructive pulmonary disease overlap syndrome" ease. 2,8,12 There are reasons for optimism that our overall management of asthma will continue to improve. There are devices that can effectively measure adherence to asthma therapy and also send reminders when medication administration is delayed.…”

The need to differentiate between adults and children when treating severe asthma

“…The majority of asthma exacerbations in both adults and children with severe asthma are precipitated by viral infections [102,103]. It is recognized that frequently exacerbations, especially in patients with severe asthma, are prolonged and less responsive to steroids, which form the mainstay of therapy.…”